Quick Answer
Seaweed Fiber Gut Health Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Conclusions : This study provides the first clinical evidence in humans that whole H.
Key Takeaways
- 01Conclusions : This study provides the first clinical evidence in humans that whole H. [Lopez-Santamarina A (2025)]
- 02Background/Objectives : Brown seaweeds, such as Himanthalia elongata , are a promising source of dietary fiber. [Lopez-Santamarina A (2025)]
- 03elongata consumption on the gut microbiota composition and short-chain fatty acid production in overweight adults. [Lopez-Santamarina A (2025)]
- 04Several studies indicated that soluble fiber can reduce serum cholesterol and glucose concentrations, as well as lower blood pressure, promote weight loss, improve insulin sensitivity and, consequently, contribute to improving metabolic syndrome and reducing morbidity and mortality associated with cardiovascular risk []. [Guerrero-Wyss Marion (2023)]
The current Migaku evidence database contains 2 reusable source documents for Seaweed Fiber Gut Health Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Conclusions : This study provides the first clinical evidence in humans that whole H. [Lopez-Santamarina A (2025); evidence level 2]
- Background/Objectives : Brown seaweeds, such as Himanthalia elongata , are a promising source of dietary fiber. [Lopez-Santamarina A (2025); evidence level 2]
- elongata consumption on the gut microbiota composition and short-chain fatty acid production in overweight adults. [Lopez-Santamarina A (2025); evidence level 2]
- Several studies indicated that soluble fiber can reduce serum cholesterol and glucose concentrations, as well as lower blood pressure, promote weight loss, improve insulin sensitivity and, consequently, contribute to improving metabolic syndrome and reducing morbidity and mortality associated with cardiovascular risk []. [Guerrero-Wyss Marion (2023); evidence level 3]
- 5 5 5 6 Metabolic syndrome is a group of disorders that occur in parallel and increase cardiovascular risk, that is, it involves a greater probability of developing coronary disease, stroke, and type 2 diabetes mellitus (T2DM) (10.4% national prevalence) []. [Guerrero-Wyss Marion (2023); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Modulation of Gut Microbiota by Whole Encapsulated Brown Seaweed (<i>Himanthalia elongata</i>) in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Trial.
- Durvillaea antarctica : A Seaweed for Enhancing Immune and Cardiometabolic Health and Gut Microbiota Composition Modulation